Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 2Phase 1/2 2Phase 1 2

Status

Withdrawn 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 13Lymphoma, Follicular 3Waldenstrom Macroglobulinemia 2Lymphoma, Non-Hodgkin 2Lymphoma, B-Cell, Marginal Zone 2Leukemia 2Lymphoma, B-Cell 1Lymphoma 1Hematologic Diseases 1

Interventions

Rituximab 59Cyclophosphamide 35Vincristine 28Doxorubicin 24Prednisone 22Bendamustine Hydrochloride 17Etoposide 15Radiotherapy 12Cytarabine 10Peripheral Blood Stem Cell Transplantation 8Filgrastim 8ibrutinib 7VAP-cyclo protocol 7Prednisolone 7Methotrexate 7Granulocyte Colony-Stimulating Factor 7ibritumomab tiuxetan 6fludarabine 6Melphalan 6Gemcitabine 6pirtobrutinib 5Mitoxantrone 5Lenalidomide 5Carmustine 5Bleomycin 5pixantrone 4Mycophenolic Acid 4Methylprednisolone 4Ifosfamide 4Idarubicin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Lymphoma, Non-Hodgkin × idelalisib × Clear all
NCT04666038 2026-04-24

BRUIN CLL-321

Eli Lilly and Company

Phase 3 Active not recruiting
238 enrolled 17 charts 1 FDA
LymphoidOther hematologic neoplasm

Hematologic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

NCT06205290 2024-04-02

A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Phase 3 Withdrawn
LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡